86 related articles for article (PubMed ID: 20386909)
1. Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors.
Traynor AM; Hewitt M; Liu G; Flaherty KT; Clark J; Freedman SJ; Scott BB; Leighton AM; Watson PA; Zhao B; O'Dwyer PJ; Wilding G
Cancer Chemother Pharmacol; 2011 Feb; 67(2):305-14. PubMed ID: 20386909
[TBL] [Abstract][Full Text] [Related]
2. A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies.
Arkenau HT; Plummer R; Molife LR; Olmos D; Yap TA; Squires M; Lewis S; Lock V; Yule M; Lyons J; Calvert H; Judson I
Ann Oncol; 2012 May; 23(5):1307-1313. PubMed ID: 22015452
[TBL] [Abstract][Full Text] [Related]
3. A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Seymour JF; Kim DW; Rubin E; Haregewoin A; Clark J; Watson P; Hughes T; Dufva I; Jimenez JL; Mahon FX; Rousselot P; Cortes J; Martinelli G; Papayannidis C; Nagler A; Giles FJ
Blood Cancer J; 2014 Aug; 4(8):e238. PubMed ID: 25127392
[TBL] [Abstract][Full Text] [Related]
4. Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study.
Blagden SP; Rizzuto I; Suppiah P; O'Shea D; Patel M; Spiers L; Sukumaran A; Bharwani N; Rockall A; Gabra H; El-Bahrawy M; Wasan H; Leonard R; Habib N; Ghazaly E
Br J Cancer; 2018 Oct; 119(7):815-822. PubMed ID: 30206366
[TBL] [Abstract][Full Text] [Related]
5. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.
Tamura K; Tsurutani J; Takahashi S; Iwata H; Krop IE; Redfern C; Sagara Y; Doi T; Park H; Murthy RK; Redman RA; Jikoh T; Lee C; Sugihara M; Shahidi J; Yver A; Modi S
Lancet Oncol; 2019 Jun; 20(6):816-826. PubMed ID: 31047803
[TBL] [Abstract][Full Text] [Related]
6. Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma.
Locke FL; Neelapu SS; Bartlett NL; Siddiqi T; Chavez JC; Hosing CM; Ghobadi A; Budde LE; Bot A; Rossi JM; Jiang Y; Xue AX; Elias M; Aycock J; Wiezorek J; Go WY
Mol Ther; 2017 Jan; 25(1):285-295. PubMed ID: 28129122
[TBL] [Abstract][Full Text] [Related]
7. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.
Santoro A; Rimassa L; Borbath I; Daniele B; Salvagni S; Van Laethem JL; Van Vlierberghe H; Trojan J; Kolligs FT; Weiss A; Miles S; Gasbarrini A; Lencioni M; Cicalese L; Sherman M; Gridelli C; Buggisch P; Gerken G; Schmid RM; Boni C; Personeni N; Hassoun Z; Abbadessa G; Schwartz B; Von Roemeling R; Lamar ME; Chen Y; Porta C
Lancet Oncol; 2013 Jan; 14(1):55-63. PubMed ID: 23182627
[TBL] [Abstract][Full Text] [Related]
8. Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors.
Lewin J; Soria JC; Stathis A; Delord JP; Peters S; Awada A; Aftimos PG; Bekradda M; Rezai K; Zeng Z; Hussain A; Perez S; Siu LL; Massard C
J Clin Oncol; 2018 Oct; 36(30):3007-3014. PubMed ID: 29733771
[TBL] [Abstract][Full Text] [Related]
9. MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia.
Giles FJ; Swords RT; Nagler A; Hochhaus A; Ottmann OG; Rizzieri DA; Talpaz M; Clark J; Watson P; Xiao A; Zhao B; Bergstrom D; Le Coutre PD; Freedman SJ; Cortes JE
Leukemia; 2013 Jan; 27(1):113-7. PubMed ID: 22772060
[TBL] [Abstract][Full Text] [Related]
10. The two sides of chromosomal instability: drivers and brakes in cancer.
Hosea R; Hillary S; Naqvi S; Wu S; Kasim V
Signal Transduct Target Ther; 2024 Mar; 9(1):75. PubMed ID: 38553459
[TBL] [Abstract][Full Text] [Related]
11. Aurora B Inhibitors as Cancer Therapeutics.
Kovacs AH; Zhao D; Hou J
Molecules; 2023 Apr; 28(8):. PubMed ID: 37110619
[TBL] [Abstract][Full Text] [Related]
12. Unusually High Affinity of the PLK Inhibitors RO3280 and GSK461364 to HSA and Its Possible Pharmacokinetic Implications.
Fernández-Sainz J; Pacheco-Liñán PJ; Ripoll C; González-Fuentes J; Albaladejo J; Bravo I; Garzón-Ruiz A
Mol Pharm; 2023 Mar; 20(3):1631-1642. PubMed ID: 36812406
[TBL] [Abstract][Full Text] [Related]
13. Ethnic and racial-specific differences in levels of centrosome-associated mitotic kinases, proliferative and epithelial-to-mesenchymal markers in breast cancers.
Rivera-Rivera Y; Vargas G; Jaiswal N; Núñez-Marrero A; Li J; Chen DT; Eschrich S; Rosa M; Johnson JO; Dutil J; Chellappan SP; Saavedra HI
Cell Div; 2022 Dec; 17(1):6. PubMed ID: 36494865
[TBL] [Abstract][Full Text] [Related]
14. Differential ABC transporter expression during hematopoiesis contributes to neutrophil-biased toxicity of Aurora kinase inhibitors.
Chou DB; Furlong BA; Posey RR; Kyprianou C; O'Sullivan LR; David R; Randle SJ; Polanska UM; Travers J; Urosevic J; Hutchinson JN; Che J; Howley AM; Hasserjian RP; Prantil-Baun R; Ingber DE
Nat Commun; 2022 Oct; 13(1):6021. PubMed ID: 36224199
[TBL] [Abstract][Full Text] [Related]
15. Chromatin bridges, not micronuclei, activate cGAS after drug-induced mitotic errors in human cells.
Flynn PJ; Koch PD; Mitchison TJ
Proc Natl Acad Sci U S A; 2021 Nov; 118(48):. PubMed ID: 34819364
[TBL] [Abstract][Full Text] [Related]
16. Second-Generation Antimitotics in Cancer Clinical Trials.
Novais P; Silva PMA; Amorim I; Bousbaa H
Pharmaceutics; 2021 Jul; 13(7):. PubMed ID: 34371703
[TBL] [Abstract][Full Text] [Related]
17. Reversing tozasertib resistance in glioma through inhibition of pyruvate dehydrogenase kinases.
Jane EP; Premkumar DR; Rajasundaram D; Thambireddy S; Reslink MC; Agnihotri S; Pollack IF
Mol Oncol; 2022 Jan; 16(1):219-249. PubMed ID: 34058053
[TBL] [Abstract][Full Text] [Related]
18. Aurora Kinase B Inhibition: A Potential Therapeutic Strategy for Cancer.
Borah NA; Reddy MM
Molecules; 2021 Apr; 26(7):. PubMed ID: 33915740
[TBL] [Abstract][Full Text] [Related]
19. Targeting AURKA in Cancer: molecular mechanisms and opportunities for Cancer therapy.
Du R; Huang C; Liu K; Li X; Dong Z
Mol Cancer; 2021 Jan; 20(1):15. PubMed ID: 33451333
[TBL] [Abstract][Full Text] [Related]
20. Aurora kinases in ovarian cancer.
Pérez-Fidalgo JA; Gambardella V; Pineda B; Burgues O; Piñero O; Cervantes A
ESMO Open; 2020 Oct; 5(5):e000718. PubMed ID: 33087400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
